Capnia, Inc.

Capnia, Inc. manufactures the CoSense® ETCOc (end-tidal carbon monoxide) Monitor, a non-invasive diagnostic device for neonatal jaundice management. The device measures hemolysis rate in newborns through breath testing, providing rapid detection of elevated bilirubin production within five minutes. CoSense® is FDA-cleared and endorsed by the American Academy of Pediatrics (AAP) as the gold-standard diagnostic test for identifying hemolytic conditions in newborns prior to discharge. The technology directly measures end-tidal carbon monoxide levels, which correlate with active hemolysis and unconjugated bilirubin overproduction, helping clinicians distinguish high-risk hemolytic cases from benign neonatal jaundice. Clinical evidence demonstrates that ETCOc testing reduces readmissions for hyperbilirubinemia, decreases unnecessary blood tests by approximately 50%, reduces phototherapy utilization by 20%, and lowers overall healthcare costs. The device supports universal screening protocols and is designed for integration into obstetric and neonatal intensive care workflows. Capnia's approach addresses kernicterus prevention by enabling early identification and treatment of hemolytic disease, particularly relevant given the narrow window for bilirubin management before discharge at 48–72 hours of life, when peak serum bilirubin typically occurs 3–5 days post-birth.